reference/27706356

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/27706356

Outgoing Links

Predicate	Object
contentType	Journal Article
endingPage	52888
issn	1949-2553
issueIdentifier	32
pageRange	52877-52888
publicationName	Oncotarget
startingPage	52877
bibliographicCitation	Wang L, Yu X, Wang C, Pan S, Liang B, Zhang Y, Chong X, Meng Y, Dong J, Zhao Y, Yang Y, Wang H, Gao J, Wei H, Zhao J, Wang H, Hu C, Xiao W, Li B. The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer. Oncotarget. 2017 Aug 08;8(32):52877–88. PMID: 28881779; PMCID: PMC5581078.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0659bdcd15e12ff9db639d0e54a75ace http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_86b0954f9380a5aa8b06ef74a12aa4f6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3e49650864256fb1a74e566e7c7f2545 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_645bd5c7c983695f685c121707d165d3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_44f305fb7b2ab50d9f6c26ccf7b50246 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3e887ec6da75a0c260970779e9400b90 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d64cffe862c64df419a290bed1f37dea http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dd0a394fea104dcdb9a652fa1affbcfa http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c47fba1bb4164a3566760a6370a6a460 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8bdc660259d478c307a7ed9859d10458 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_76879411ecc73e24413706bdf21a4c8a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f50dc1d3c70ed45f75a3953f0d0e82e0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_17ca41660a14d373b62a65fd59fb9f67 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a422ee4e45e9d76caf9a549c836bb047 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_be1c3f2398ed72f144df4f1deb64a220 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9abfc2ac7cd806889cc56956eb34598d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_449c83b5c3a1cce7dc18ad54e13eec4a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_446041e2d2b1d64c1b1d1eb8d3148297 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f0f070d5dcd45e4711733480cf9e9a10
date	2017-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/28881779 https://doi.org/10.18632/oncotarget.17907 https://pubmed.ncbi.nlm.nih.gov/PMC5581078
isPartOf	https://portal.issn.org/resource/ISSN/1949-2553 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/37803
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID17755052 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_c7be83279551b50c0e81dc2dbfe3c5d8 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7102 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_95d926625e5919a35cb6aa367ba7b069 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_1ab93dab864d412d37c9dcb9c25f8a38 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_43830973f74de180729ad1e755d592ad http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fadc3c8509db129e10ef4cfccf6efc5d

Total number of triples: 46.